PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

27 August 2021 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Qidi Ying

Ningbo NO2 Hospital, Ningbo (China)

17 More presentations in this session

Presentation thumbnail

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Mr A. Holt (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Mr A. Holt (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Doctor M. Delbeck (Wuppertal, DE)

Abstract Slides

Presentation thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Assistant Professor H. Fukaya (Sagamihara, JP)

Abstract Slides

Presentation thumbnail

Renal decline in patients with atrial fibrillation treated with rivaroxaban or warfarin: a population-based cohort study in the United Kingdom

Doctor Y. Lenz (Berlin, DE)

Abstract Slides

Access the full session

Session thumbnail

Congress committee e-posters choice in pharmacology and pharmacotherapy

The Event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

You may be interested in

Congress Presentation

Lipid control in cardiovascular patients

Congress Presentation

What’s new in LDL lowering?

Congress Presentation

Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources